Abstracts Archive - Page 1950 of 2425 - ACR Meeting Abstracts

Abstract Number: 1541 • 2014 ACR/ARHP Annual Meeting
Distinct Regulation of T Helper Cell Differentiation By Biologic DMARD Therapy in Rheumatoid Arthritis
Shingo Nakayamada¹, Satoshi Kubo¹, Maiko Yoshikawa¹, Naoki Yunoue¹, Yusuke Miyazaki¹, Kazuyoshi Saito¹ and Yoshiya Tanaka², ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: In the pathogenesis of rheumatoid arthritis (RA), T helper cells can differentiate into functionally distinct subsets, leading to the persistent inflammation and immune abnormality…
Abstract Number: 1540 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Biologics Used in Rheumatoid Arthritis and Ankylosing Spondylitis in the US Veterans Population
Brian Sauer¹, Chia-Chen Teng¹, Tao He¹, Jianwei Leng², Chao-Chin Lu¹, Neel Shah³, David J. Harrison⁴, Derek Tang⁴ and Grant W. Cannon⁵, ¹Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Salt Lake City VA and University of Utah, Salt Lake Citty, UT, ³1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Biologics used for rheumatoid arthritis (RA) and ankylosing spondylitis (AS), including tumor necrosis factor blockers, are a key area of focus for Veterans Affairs…
Abstract Number: 1539 • 2014 ACR/ARHP Annual Meeting
Relation Between Number of Previous Anti TNF Agents and Clinical Response in Rheumatoid Arthritis Patients Treated with Rituximab
Daniela Opris¹, Diana Mazilu², Violeta Bojinca³, Andreea Borangiu², Andra Balanescu⁴, Denisa Predeteanu⁵ and Ruxandra Ionescu⁴, ¹53 Tineretului Blvd, Bl. 65, s, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ²Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ³Intr. Carol Knappe Nr. 9A, Sec, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ⁴Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ⁵Bld.Mircea Voda Nr 36., Bl M6,, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania
Background/Purpose Debate is still ongoing regarding rituximab (RTX) as a first or second line biologic therapy. The objective of present study is to assess correlations between…
Abstract Number: 1538 • 2014 ACR/ARHP Annual Meeting
Sustained Clinical Benefit with Multiple Courses of Rituximab in Second LineÂ forÂ All Rheumatoid Arthtritis PatientsÂ Irrespective to the Inhibitor of Tumour Necrosis FactorÂ Previously Used
Ioan Ancuta¹, Ruxandra Ionescu², Catalin Codreanu³, Andra Balanescu², Elena Rezus⁴, Maria Suta⁵, Paulina Ciurea⁶, Mihaela Milicescu⁷, Dan Nemes⁸, Codrina Ancuta⁹, Mihai Bojinca¹⁰, Magda Parvu¹¹ and Horatiu Popoviciu¹², ¹“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ³5 Thomas Masaryk Street, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ⁴Rheumatology, Recovering Clinical Hospital, Iasi, Romania, ⁵317 Tomis Str. , Bl. 4A, ap. 3, Constanta Municipal Hospital, Constanta, Romania, ⁶Clinical County Hospital,Craiova, Craiova, Romania, ⁷Rheumatology, "Dr. I. Cantacuzino" Clinical Hospital, Bucharest, Romania, ⁸Rehabilitation and Rheumatology, ”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, ⁹G.T.Popa Center for Biomedical Research, Iasi, Romania, ¹⁰Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ¹¹Rheumatology, Colentina Clinical Hospital, Bucuresti, Romania, ¹²Rheumatology, University of Medicine and Pharmacy Targu Mures, Tg Mures, Romania
Background/Purpose: In the last decade, biologic therapy changed dramatically treatment options for rheumatoid arthritis (RA). However, a significant number of patients failed to maintain the…
Abstract Number: 1537 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics of RA Patients Newly Prescribed Tofacitinib Citrate (tofacitinib) in the United States after Food and Drug Administration Approval: Results from the Corrona US Rheumatoid Arthritis Registry
Arthur Kavanaugh¹, George W. Reed^2,3, Katherine C. Saunders², Andrew S. Koenig⁴, Jamie Geier⁵, Joel M. Kremer⁶, Jeffrey D. Greenberg^2,7 and Clifton O. Bingham III⁸, ¹University of California San Diego, La Jolla, CA, ²Corrona, LLC., Southborough, MA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Pfizer, Inc., Collegeville, PA, ⁵Pfizer, Inc., New York, NY, ⁶Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁷Rheumatology, New York University School of Medicine, New York, NY, ⁸Johns Hopkins University, Baltimore, MD
Background/Purpose: To provide initial characterization of the patients prescribed tofacitinib during the early period after United States (US) Food and Drug Administration (FDA) approval (11/6/2012).…
Abstract Number: 1536 • 2014 ACR/ARHP Annual Meeting
Comparing Abatacept to Adalimumab, Etanercept and Infliximab As First Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Isabelle Fortin³, Boulos Haraoui¹, Jean Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard⁴, Diane Sauvageau¹, Edith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁴Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: The order of use of biologic agents is still a question for debate. Phase III trial data in MTX-IR patients show comparable efficacy results…
Abstract Number: 1535 • 2014 ACR/ARHP Annual Meeting
Use of Rituximab Compared to Anti-Tnf Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: A Report from the rhumadata® Clinical Database and registry
Denis Choquette¹, Jean-Pierre Raynauld¹, Jean Pierre Pelletier¹, Boulos Haraoui¹, Louis Bessette², Edith Villeneuve¹, Marie-Anaïs Rémillard³, Isabelle Fortin⁴, Diane Sauvageau¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁴Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada
Background/Purpose: The order of use of biologic agents after failing a TNF inhibitor is still a question for debate. Phase III trial data in TNF-IR…
Abstract Number: 1534 • 2014 ACR/ARHP Annual Meeting
Disease Severity and Treatment of Rheumatoid Arthritis: A Comparative Study Between Sudan and Sweden
Amir Elshafie¹, Abdalla D Elkhalifa², Thomas Weitoft³, Musa Nur⁴, Elnour Elagib⁵, Mawahib Aledrissy⁶, Sahwa Elbagir⁷ and Johan Rönnelid⁸, ¹Immunology, Genetics and Pathology, MD, MDpath, PhD, Uppsala, Sweden, ²Rheumatology unit, MD, Gävle, Sweden, ³Rheumatology unit, MD, PhD, Gävle, Sweden, ⁴Alribat University Hospital, MD, FRCP, Khartoum, Sudan, ⁵Rheumatology unit, Alribat University Hospital, MD, FRCP, Khartoum, Sudan, ⁶Rheumatology unit, Alribat University Hospital, MD, MD internal Medicine, Khartoum, Sudan, ⁷Immunology, Genetics and Pathology, M, PhD student, Uppsala, Sweden, ⁸Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
Background/Purpose: To perform a comparative study concerning clinical characteristics and treatment between Sudanese and Swedish RA outpatients. Methods: A 286 Sudanese and 542 Swedish RA…
Abstract Number: 1516 • 2014 ACR/ARHP Annual Meeting
TNF-Alpha Inhibitors Normalizes Melanocortin Receptor Subtype 2, 3 and 4 Expression in CD8+, CD14+ and CD19+ Leukocyte Subsets in Rheumatoid Arthritis
Marlene Andersen¹, Michael Kruse Meyer², Ivan Nagaev³, Olga Nagaeva³, Jarl E.S. Wikberg⁴, Lucia Mincheva-Nilsson³ and Grethe N. Andersen², ¹Department of Rheumatology, Aalborg University, Hjørring, Denmark, ²Clinic of Rheumatology, Hospital of Vendsyssel/Aalborg University, Hjørring, Denmark, ³Department of Clinical Immunology, University of Umeå, Umeå, Sweden, ⁴Department of Pharmaceutical Biosciences, Department of Pharmaceutical Pharmacology, Uppsala, Sweden
Background/Purpose: We examined Adalimumab´s effects on melanocortin receptor subtype (MC)1-5 gene expression in important leukocyte subsets in rheumatoid arthritis (RA). The melanocortin system is a…
Abstract Number: 1515 • 2014 ACR/ARHP Annual Meeting
The Impact on Anti-Citrullinated Protein Antibody Isotypes and Epitope Fine Specificity in Patients with Early RA Treated with Abatacept and Methotrexate
T W J Huizinga¹, S E Connolly², Daniel E. Furst³, Vivian P. Bykerk⁴, Gerd Burmester⁵, B G Combe⁶, C S Karyekar², D Wong², L Trouw¹, R E M Toes⁷ and P Emery⁸, ¹Leiden University Medical Center, Leiden, Netherlands, ²Bristol-Myers Squibb, Princeton, NJ, ³University of California at Los Angeles, Los Angeles, CA, ⁴Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁵Charité – University Medicine Berlin, Berlin, Germany, ⁶Montpellier University Hospital, Montpellier, France, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸University of Leeds, Leeds, United Kingdom
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a marker of RA and may contribute to disease progression.1,2 ACPA analysis in patients offers the opportunity to estimate…
Abstract Number: 1514 • 2014 ACR/ARHP Annual Meeting
An Analysis of in-Vitro Cytokine Inhibition Profiles of Tofacitinib and Other Janus Kinase Inhibitors at Clinically-Meaningful Concentrations
M.E. Dowty, T.S. Lin, L. Wang, J. Jussif, B. Juba, L. Li, E. Moy and J.-B. Telliez, Pfizer Worldwide R&D, Cambridge, MA
Background/Purpose: A number of Janus kinase (JAK) inhibitors are being actively investigated for treatment of rheumatoid arthritis (RA), including tofacitinib, baricitinib, filgotinib (GLPG0634), and decernotinib…
Abstract Number: 1513 • 2014 ACR/ARHP Annual Meeting
Selection of Vagus Nerve Stimulation Parameters for a First-in-Human Study in Rheumatoid Arthritis: A Unique Translational Medicine Challenge
Frieda A. Koopman¹, Yaakov Levine², Mike Faltys², Ralph Zitnik² and Paul P. Tak³, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²SetPoint Medical Corporation, Valencia, CA, ³Departments of Experimental Immunology and Internal Medicine, GlaxoSmithKline U.K. and Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Cholinergic anti-inflammatory pathway (CAP) activation by electrical vagus nerve stimulation (VNS) is being studied in rheumatoid arthritis (RA) trials (NCT01552941). CAP signaling proceeds sequentially…
Abstract Number: 1512 • 2014 ACR/ARHP Annual Meeting
Therapeutic Efficacy of a Novel Oral Small Molecule Macrophage Migration Inhibitory Factor [MIF] Inhibitor: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
Anderson Gaweco^1,2, Samantha Palmer², Rambon Shamilov², Caroline Stremnitzer², Michael Fisher², Gregg Crichlow², William Windsor², Ellen M. Ginzler³ and Jefferson Tilley², ¹SUNY-Downstate Medical Center, Brooklyn, NY, ²Innovimmune Biotherapeutics, Brooklyn, NY, ³Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: Macrophage migration inhibitory factor [MIF] is a cytokine secreted by activated T cells and macrophages that plays an important role in RA and autoimmune…
Abstract Number: 1511 • 2014 ACR/ARHP Annual Meeting
COVA322: A Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Wibke Lembke, Bernd Schlereth, Julian Bertschinger, Dragan Grabulovski and Mathias Locher, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologic therapeutics such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, including rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there is still…
Abstract Number: 1510 • 2014 ACR/ARHP Annual Meeting
Blockade of TLR5 Ligation Is a Novel Strategy for RA Therapy
Seung-jae Kim¹, Zhenlong Chen¹, Abdul Essani², Michael Volin³, Suncica Volkov¹, William Swedler⁴, Shiva Arami², Nadera J. Sweiss⁵ and Shiva Shahrara¹, ¹Medicine/Rheumatology, University of Illinois at Chicago, Chicago, IL, ²University of Illinois at Chicago, Chicago, IL, ³Microbiology & Immunology, Midwestern University, Downers Grove, IL, ⁴Section of Rheumatology, University of Illinois at Chicago, Chicago, IL, ⁵internal medicine section of rheumatology, University of Illinois at Chicago, Chicago, IL
Background/Purpose: TLR5 expression is highly elevated in RA and CIA lining and sublining macrophages and endothelial cells compared to non-arthritic controls. Additionally, expression of TLR5…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].